Clinical Trials
8 trialsNCT02470585 2024-10-26
VELIA
AbbVie
Phase 3 Terminated
NCT03400306 2021-12-08
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
AbbVie
Phase 1 Withdrawn
NCT01113957 2018-06-06
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
AbbVie
Phase 2 Completed
NCT02210663 2018-05-07
A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT00526617 2017-11-21
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
AbbVie
Phase 1 Completed
NCT02009631 2017-11-20
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
AbbVie
Phase 1 Completed
NCT02483104 2017-11-20
Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer
AbbVie
Phase 1 Completed
NCT02033551 2016-09-27
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
AbbVie
Phase 1 Completed